Remove investors syndicates
article thumbnail

A Survey of Private Debt Funds

Harvard Corporate Governance

and 153 European private debt investors managing roughly 35% of assets under management (AuM) of the private debt market. Accordingly, in this post, we survey and ask a broad set of questions to a meaningful group of private debt general partners (GPs). They comprise of 38 U.S.

Banking 220
article thumbnail

Paul Weiss Discusses Second Circuit Decision Confirming Syndicated Bank Loan Not a “Security”

Reynolds Holding

affirmed dismissal of state-law securities claims because the syndicated term loan in question was not a “security” and therefore not subject to state and federal securities laws and regulations. [1] In May 2020, the district court found that the syndicated bank loan at issue was not a security and dismissed the case. [2]

Banking 40
Insiders

Sign Up for our Newsletter

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

article thumbnail

Cleary Discusses Second Circuit Decision That Syndicated Loans Are Not Securities

Reynolds Holding

JP Morgan Chase , [1] concluding that the plaintiff failed to adequately plead that the syndicated term loans at issue were securities. Background The dispute in Kirschner arose out of a $1.775 billion syndicated loan transaction that closed on April 16, 2014. [4] The loans were evidenced by notes (the “Notes”). [5]

Banking 40
article thumbnail

How Alliance Politics Skews Corporate Debt Restructurings

Reynolds Holding

These transactions, which I called in a previous article “hostile restructurings,” are distinguishable from normal debt restructurings by their use of aggressive tactics to overcome not only the traditional minority-lender holdout problem, but also the collective bargaining power of an entire syndicated lender group.

article thumbnail

IBN Coverage Initiated for Bravo Multinational Inc.

Benzinga

As part of the Client Partner relationship, IBN will leverage its investor based distribution network of 5,000+ key syndication outlets , Full story available on Benzinga.com

Beta 40
article thumbnail

First Wave BioPharma Announces Completion of Business Combination with ImmunogenX, Adding Phase 3-Ready Latiglutenase to its Late-Stage GI-Focused Clinical Pipeline

Benzinga

First Wave BioPharma will also seek to secure financing commitments from a syndicate of institutional healthcare investors to fund the ongoing development of latiglutenase. and Canadian rights to the drug and to obtain financing with a syndicate of leading institutional healthcare funds in 2H'24.

Finance 40
article thumbnail

Tourmaline Bio Announces Closing of Merger with Talaris Therapeutics and Concurrent Private Placement of $75 Million

Benzinga

The combined company will operate under the name, Tourmaline Bio, Inc., and its shares are expected to begin trading on the Nasdaq Global Market on October 20, 2023 under the ticker symbol "TRML".